Influence of an abnormal ankle-brachial index on ischemic and bleeding events in patients undergoing percutaneous coronary intervention
1
조회
0
다운로드
1
인용
0
참고문헌
키워드
초록
Background/Aims: Bleeding events after percutaneous coronary intervention (PCI) have important prognostic implications. Data on the influence of an abnormal ankle-brachial index (ABI) on both ischemic and bleeding events in patients undergoing PCI are limited. Methods: We included patients who underwent PCI with available ABI data (abnormal ABI, ≤ 0.9 or > 1.4). The primary endpoint was the composite of all-cause death, myocardial infarction (MI), stroke, and major bleeding. Results: Among 4,747 patients, an abnormal ABI was observed in 610 patients (12.9%). During follow-up (median, 31 months), the 5-year cumulative incidence of adverse clinical events was higher in the abnormal ABI group than in the normal ABI group: primary endpoint (36.0% vs. 14.5%, log-rank test, p < 0.001); all-cause death (19.4% vs. 5.1%, log-rank test, p < 0.001); MI (6.3% vs. 4.1%, log-rank test, p = 0.013); stroke (6.2% vs. 2.7%, log-rank test, p = 0.001); and major bleeding (8.9% vs. 3.7%, log-rank test, p < 0.001). An abnormal ABI was an independent risk factor for all-cause death (hazard ratio [HR], 3.05; p < 0.001), stroke (HR, 1.79; p = 0.042), and major bleeding (HR, 1.61; p = 0.034). Conclusions: An abnormal ABI is a risk factor for both ischemic and bleeding events after PCI. Our study findings may be helpful in determining the optimal method for secondary prevention after PCI.
Abstract
Background/Aims: Bleeding events after percutaneous coronary intervention (PCI) have important prognostic implications. Data on the influence of an abnormal ankle-brachial index (ABI) on both ischemic and bleeding events in patients undergoing PCI are limited. Methods: We included patients who underwent PCI with available ABI data (abnormal ABI, ≤ 0.9 or > 1.4). The primary endpoint was the composite of all-cause death, myocardial infarction (MI), stroke, and major bleeding. Results: Among 4,747 patients, an abnormal ABI was observed in 610 patients (12.9%). During follow-up (median, 31 months), the 5-year cumulative incidence of adverse clinical events was higher in the abnormal ABI group than in the normal ABI group: primary endpoint (36.0% vs. 14.5%, log-rank test, p < 0.001); all-cause death (19.4% vs. 5.1%, log-rank test, p < 0.001); MI (6.3% vs. 4.1%, log-rank test, p = 0.013); stroke (6.2% vs. 2.7%, log-rank test, p = 0.001); and major bleeding (8.9% vs. 3.7%, log-rank test, p < 0.001). An abnormal ABI was an independent risk factor for all-cause death (hazard ratio [HR], 3.05; p < 0.001), stroke (HR, 1.79; p = 0.042), and major bleeding (HR, 1.61; p = 0.034). Conclusions: An abnormal ABI is a risk factor for both ischemic and bleeding events after PCI. Our study findings may be helpful in determining the optimal method for secondary prevention after PCI.
참고문헌 (31)
- Fowkes FG, "Peripheral artery disease : epidemiology and global perspectives", Nat Rev Cardiol, 14, pp.156~170 (2017)
- Eagle KA, "Longterm survival in patients with coronary artery disease : importance of peripheral vascular disease. The coronary artery surgery study(CASS)investigators", J Am Coll Cardiol, 23, pp.1091~1095 (1994)
- Bhatt DL, "Prior polyvascular disease : risk factor for adverse ischaemic outcomes in acute coronary syndromes", Eur Heart J, 30, pp.1195~1202 (2009)
- Gerhard-Herman MD, "2016AHA", ACC guideline on the management of patients with lower extremity peripheral artery disease : a report of the American College of Cardiology, Circulation, pp.2017, 135[DOI]
- Bevan GH, "Evidence-based medical management of peripheral artery disease", Arterioscler Thromb Vasc Biol, 40, pp.541~553 (2020)
- Criqui MH, "Lower extremity peripheral artery disease : contemporary epidemiology, management gaps, and future directions : a scientific statement from the American Heart Association", Circulation, 144, pp.e171~e191 (2021)
- Gutierrez JA, "Polyvascular disease and risk of major adverse cardiovascular events in peripheral artery disease : a secondary analysis of the Euclid trial", JAMA Netw Open, 1, pp.e185239~ (2018)
- Jukema JW, "Alirocumab in patients with polyvascular disease and recent acute coronary syndrome : ODYSSEY OUTCOMES trial", J Am Coll Cardiol, 74, pp.1167~1176 (2019)
- Eikelboom JW, "Rivaroxaban with or without aspirin in stable cardiovascular disease", N Engl J Med, 377, pp.1319~1330 (2017)
- Anand SS, "Rivaroxaban with or without aspirin in patients with stable peripheral or carotid artery disease : an international, randomised, double-blind, placebo-controlled trial", Lancet, 391, pp.219~229 (2018)
- Aboyans V, "Measurement and interpretation of the ankle-brachial index : a scientific statement from the American Heart Association", Circulation, 126, pp.2890~2909 (2012)
- European Stroke Organisation, "ESC guidelines on the diagnosis and treatment of peripheral artery diseases : document covering atherosclerotic disease of extracranial carotid and vertebral, mesenteric, renal, upper and lower extremity arteries : the task force on the diagnosis and treatment of peripheral artery diseases of the European Society of Cardiology(ESC)", Eur Heart J, 32, pp.2851~2906 (2011)
- Lee JY, "Prevalence and clinical implications of newly revealed, asymptomatic abnormal ankle-brachial index in patients with significant coronary artery disease", JACC Cardiovasc Interv, 6, pp.1303~1313 (2013)
- Ban S, "Association of asymptomatic low ankle-brachial index with long-term clinical outcomes in patients after acute myocardial infarction", J Atheroscler Thromb, 29, pp.992~1000 (2022)
- Carter SA, "Indirect systolic pressures and pulse waves in arterial occlusive diseases of the lower extremities", Circulation, 37, pp.624~637 (1968)
- Suominen V, "PAD as a risk factor for mortality among patients with elevated ABI--a clinical study", Eur J Vasc Endovasc Surg, 39, pp.316~322 (2010)
- Garcia-Garcia HM, "Standardized end point definitions for coronary intervention trials : the academic research consortium-2 consensus document", Circulation, 137, pp.2635~2650 (2018)
- Mehran R, "Standardized bleeding definitions for cardiovascular clinical trials : a consensus report from the Bleeding Academic Research Consortium", Circulation, 123, pp.2736~2747 (2011)
- Bhatt DL, "International prevalence, recognition, and treatment of cardiovascular risk factors in outpatients with atherothrombosis", JAMA, 295, pp.180~189 (2006)
- Hiramori S, "Clinical impact of the ankle-brachial index in patients undergoing successful percutaneous coronary intervention", Circ J, 82, pp.1675~1681 (2018)
- Nakahashi T, "Impact of decreased ankle-brachial index on 30-day bleeding complications and longterm mortality in patients with acute coronary syndrome after percutaneous coronary intervention", J Cardiol, 74, pp.116~122 (2019)
- Urban P, "Defining high bleeding risk in patients undergoing percutaneous coronary intervention", Circulation, 140, pp.240~261 (2019)
- Cao D, "Validation of the Academic Research Consortium high bleeding risk definition in contemporary PCI patients", J Am Coll Cardiol, 75, pp.2711~2722 (2020)
- Kim HK, "The East Asian paradox : an updated position statement on the challenges to the current antithrombotic strategy in patients with cardiovascular disease", Thromb Haemost, 121, pp.422~432 (2021)
- Matsuura Y, "Optimal antithrombotic therapy in patients undergoing percutaneous coronary intervention : a focused review on high bleeding risk", J Atheroscler Thromb, 29, pp.1409~1420 (2022)
- Sotomi Y, "Practical assessment of the tradeoff between fatal bleeding and coronary thrombotic risks using the academic research consortium for high bleeding risk criteria", J Atheroscler Thromb, 29, pp.1236~1248 (2022)
- Jönelid B, "Ankle brachial index most important to identify polyvascular disease in patients with non-ST elevation or ST-elevation myocardial infarction", Eur J Intern Med, 30, pp.55~60 (2016)
- Ankle Brachial Index Collaboration, "Ankle brachial index combined with Framingham Risk Score to predict cardiovascular events and mortality : a meta-analysis", JAMA, 300, pp.197~208 (2008)
- Soga Y, "Two-year life expectancy in patients with critical limb ischemia", JACC Cardiovasc Interv, 7, pp.1444~1449 (2014)
- Rein P, "Systemic inflammation is higher in peripheral artery disease than in stable coronary artery disease", Atherosclerosis, 239, pp.299~303 (2015)
- Bae JS, "The Impact of platelet-fibrin clot strength on occurrence and clinical outcomes of peripheral artery disease in patients with significant coronary artery disease", J Thromb Thrombolysis, 50, pp.969~981 (2020)